Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 36Neoplasms 7Neoplasm Metastasis 7Endometrial Neoplasms 7Ovarian Neoplasms 5Triple Negative Breast Neoplasms 4Breast Diseases 3Brain Neoplasms 3Sarcoma 2Neoplasms by Site 2Meningioma 2Glioblastoma 2Fallopian Tube Neoplasms 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Sarcoma, Kaposi 1Retinoblastoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Osteosarcoma 1Neurofibromatosis 1 1Neoplasm, Residual 1Multiple Myeloma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1

Interventions

trametinib 2fludarabine 2thymoglobulin 1talimogene laherparepvec 1fludarabine phosphate 1dabrafenib 1abemaciclib 1Waiting Lists 1Rituximab 1Photochemotherapy 1Melphalan 1Liquid Biopsy 1Levetiracetam 1Injections 1Cytarabine 1Cyclophosphamide 1Busulfan 1Azacitidine 1Aminolevulinic Acid 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neurofibromatosis 1 × abemaciclib × Clear all
NCT04750928 2026-04-24

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
55 enrolled
CNS

Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡